Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Rare Diseases 1Neuromyelitis Optica 1Neurologic Manifestations 1Myelitis, Transverse 1Multiple Sclerosis 1Mental Disorders 1Encephalomyelitis, Acute Disseminated 1Diffuse Cerebral Sclerosis of Schilder 1

Interventions

Cisplatin 130Radiotherapy 94Carboplatin 85Paclitaxel 78Fluorouracil 78Cyclophosphamide 77Gemcitabine 72Capecitabine 66Docetaxel 65Doxorubicin 60Oxaliplatin 59Etoposide 57Leucovorin 49Vincristine 47Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Neoadjuvant Therapy 28Pemetrexed 27Tamoxifen 25Prednisone 24Irinotecan 24Rituximab 21Methotrexate 21Radiotherapy, Intensity-Modulated 19apatinib 18Vinorelbine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Plasma Exchange × Clear all
NCT00004645 2005-06-24

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

Office of Rare Diseases (ORD)

Phase 3 Unknown
22 enrolled

Mental Disorders, Diffuse Cerebral Sclerosis of Schilder, Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myelitis, Transverse, Neurologic Manifestations, Neuromyelitis Optica, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡